Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7834430 | 0.89 | HTR1A (0.51) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL7004124 | 0.87 | BCHE (0.50) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL7004776 | 0.84 | HTR1A (0.49) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL6215213 | 0.81 | MAPT (0.67) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL4198960 | 0.80 | MAPT (0.44) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL183414 | 0.78 | MAPT (0.48) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL7665943 | 0.78 | THRA (0.51) | MAPTL3MBTL1MAPK1TDP1MAPK14 | |
| SCHEMBL7668210 | 0.78 | HTR1A (0.45) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL27716224 | 0.78 | KDM1A (0.46) | MAPTL3MBTL1MAPK1TDP1HTR1A | |
| SCHEMBL2767880 | 0.78 | L3MBTL1 (0.48) | MAPTL3MBTL1MAPK1TDP1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324220-B2 | Process for the preparation of isoxazoline compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-05-10 | — | — | US | claimed |
| EP-3440062-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ISOXAZOLINE COMPOUNDS - CRYSTALLINE TOLUENE SOLVATE OF (S)-AFOXOLANER | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-10-06 | — | — | EP | claimed |
| US-20210022344-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-01-28 | — | — | US | claimed |
| US-10433552-B2 | Process for the preparation of isoxazoline compounds | MERIAL, INC. (US) | 2019-10-08 | — | — | US | claimed |
| EP-3440062-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ISOXAZOLINE COMPOUNDS - CRYSTALLINE TOLUENE SOLVATE OF (S)-AFOXOLANER | Merial, Inc. (US) | 2019-02-13 | — | — | EP | claimed |
| CN-109195955-A | Process for the preparation of crystalline toluene solvates of enantiomerically enriched isoxazoline compound- (S) -afoxolaner | 梅里亚股份有限公司 | 2019-01-11 | — | — | CN | claimed |
| US-20170311601-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS | MERIAL INC. (US) | 2017-11-02 | — | — | US | claimed |
| WO-2017176948-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ISOXAZOLINE COMPOUNDS - CRYSTALLINE TOLUENE SOLVATE OF (S)-AFOXOLANER | MERIAL, INC. (US) | 2017-10-12 | — | — | WO | claimed |
| CN-109195955-B | Process for the preparation of crystalline toluene solvates of enantiomerically enriched isoxazoline compound- (S) -afoxolaner | 勃林格殷格翰动物保健美国公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114805234-A | Process for the preparation of crystalline toluene solvates of enantiomerically enriched isoxazoline compound- (S) -afoxolaner | 勃林格殷格翰动物保健美国公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11324220-B2 | Process for the preparation of isoxazoline compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3440062-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ISOXAZOLINE COMPOUNDS - CRYSTALLINE TOLUENE SOLVATE OF (S)-AFOXOLANER | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210022344-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-01-28 | — | — | US | disclosed |
| US-10750744-B2 | Process for the preparation of isoxazoline compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| EP-1081149-A1 | PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0778267-A1 | SULFONAMIDE DERIVATIVES AND INSECTICIDE, MITICIDE AND NEMATICIDE CONTAINING THE SAME | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-06-11 | — | — | EP | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10750744-B2 | Process for the preparation of isoxazoline compounds | CYP3A7, CYP3A4, CYP3A5 | MAPT 1694/4885L3MBTL1 4260/4885MAPK1 3132/4885 |
| US-20210022344-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS | CYP3A7, CYP3A4, CYP3A5 | MAPT 1694/4885L3MBTL1 4260/4885MAPK1 3132/4885 |
| US-20170311601-A1 | PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS | CYP3A7, CYP3A4, CYP3A5 | MAPT 1694/4885L3MBTL1 4260/4885MAPK1 3132/4885 |
| US-10433552-B2 | Process for the preparation of isoxazoline compounds | CYP3A7, CYP3A4, CYP3A5 | MAPT 1694/4885L3MBTL1 4260/4885MAPK1 3132/4885 |
| US-11324220-B2 | Process for the preparation of isoxazoline compounds | CYP3A7, CYP3A4, CYP3A5 | MAPT 1694/4885L3MBTL1 4260/4885MAPK1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.